Kanvas Biosciences

Kanvas Biosciences enables the development of next generation life biotherapeutics through its first-in-category platforms.

The company presented data at SITC indicating that the microbiome can have a clinical impact.

The company will transition from R&D and process development into GMP manufacturing to support Phase 1 and 2 clinical trials.

KAN-001 is a fully defined live biotherapeutic product comprising dozens of strains.

Preclinical studies evaluated KAN-004 in two murine models of antibiotic-induced dysbiosis.

Kanvas Biosciences received clearance to begin the first-patient-in stage of a Phase 1 clinical trial of KAN-004.

The company describes its team as committed to inclusivity, diversity, and respect.

Aditya led the Process and Analytical Development team at Federation Bio.

Hao is deeply passionate about building precision measurement tools for biology.

Lee Swem is the chief development officer at Kanvas Biosciences and leads development of microbial LBP products.

Matt joined McGill University Health Center as a clinician-scientist.

At the core of Kanvas Biosciences is a group of curious and passionate innovators committed to upend outdated thinking about the microbiome.

The company is headquartered in Monmouth Junction, New Jersey, and has a West Coast location in San Francisco, CA.

Kanvas Biosciences developed imaging technology to map the microbiome and develop therapeutics.

Kanvas Biosciences has developed imaging technology to map the microbiome and develop therapeutics.

Kanvas Biosciences raises USD 48 million in Series A funding to support a clinical trial of its lead cancer immunotherapy treatment. The financing also advances the company’s microbiome therapeutics.

Jun 2026 · Cornell ChronicleNews article

Kanvas Biosciences raises USD 48 million in Series A funding co-led by DCVC and Lions Capital. The company will use the financing to advance its microbiome cancer therapies toward clinical trials.

May 2026 · FinSMEsNews article

Kanvas Biosciences, founded by Hao Shi, Iwijn De Vlaminck and Matthew Cheng, is advancing its KAN-001 and KAN-004 live biotherapeutics toward clinical trials.

Jun 2025 · Cornell ChronicleNews article

Kanvas Bioscience research reports that its HiPR-Map platform can outperform traditional sequencing methods for live biotherapeutic product discovery and development.

Apr 2025 · Pharmaceutical ExecutiveNews article